Related content

Improved Migraine Treatment Outcomes with Rizatriptan 10 mg Compared to Non-triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

By Torrecilla M.   Caloto M.T.   Nocea G.   Gerth W.C.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 50-54

Informa Healthcare

Access to resources Recommend Favorite

Is migraine a disease?

By Cortelli Pietro   Pierangeli G.   Montagna P.  

Neurological Sciences, Vol. 31, Iss. 1, 2010-06 ,pp. : 29-31

Springer Publishing Company

Access to resources Recommend Favorite

Improved 24-Hour Migraine Quality of Life with Rizatriptan 10 mg compared to Non-Triptan Treatment. I-MAX Migraine Disability Assessment Program, Spain

By Gerth W.C.   Bertral C.   Ester F.   Castellanos A.   Caloto M.T.   Nocea G.  

Headache Care, Vol. 1, Iss. 1, 2004-03 ,pp. : 46-49

Informa Healthcare

Access to resources Recommend Favorite

Value and utility of disease-specific and generic instruments for assessing disability in patients with migraine, and their relationships with health-related quality of life

By Raggi Alberto   Leonardi Matilde   Bussone Gennaro   D’Amico Domenico  

Neurological Sciences, Vol. 32, Iss. 3, 2011-06 ,pp. : 387-392

Springer Publishing Company

Access to resources Recommend Favorite

Genetic modification of cerebral arterial wall: implications for prevention and treatment of cerebral vasospasm

By Vijay Anantha   Santhanam R.   Katusic Zvonimir S.  

Neurological Research, Vol. 28, Iss. 7, 2006-10 ,pp. : 759-768

Maney Publishing

Access to resources Recommend Favorite